Author Archives: Warren Woessner

Upcoming AUTM Webinar Examines Avoiding the Trap of Inequitable Conduct

On March 4, an AUTM webinar will discuss, “Inequitable Conduct: How to Protect Your Patents from this Unenforceability Trap”. This presentation will take place from 12 p.m. to 1:30 p.m. Eastern time this Thursday. Panelists will include David Hricik of … Continue reading

Posted in Inequitable Conduct/Rule 56, Webinar | Tagged , | Leave a comment

Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear

While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are … Continue reading

Posted in Enablement | Tagged , , | Leave a comment

Illumina v. Ariosa – Ariosa Petitions for Cert.

The first panel decision below can be found at 952 F.3d 1367 (Fed. Cir. 2020). I posted on this decision on June 1, 2020, days before the Fed. Cir. issued a modified panel decision in August, 967 F.3d 1319 (Fed. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment

American Axle & Manufacturing v. Neapco Holdings–Part II

In my first post on American Axle’s Petition for cert., I focused on the substantive arguments of the parties. Almost as interesting is Part 5 of the Petition, in which AA argues that this is a good case for the … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , | Leave a comment